The Pan-Immune-Inflammation Value in Patients with Metastatic Melanoma Receiving First-Line Therapy.

Giovanni FucàTeresa BeninatoMarta BiniLaura MazzeoLorenza Di GuardoCarolina CimminielloGiovanni RandonGiulia ApollonioIlaria BisognoMarta Del VecchioClaudia Lauria PantanoMassimo Di NicolaFilippo de BraudMichele Del Vecchio

Published in: Targeted oncology (2021)

PIV may guide the treatment decision process and the development of novel first-line treatment strategies in melanoma, but warrants further study and validation.

Keyphrases

oxidative stress
decision making

cell therapy

bone marrow

basal cell carcinoma